Interview with Carlos Gallardo, General Manager UK & Ireland, Almirall UK
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
Address: 1 The Square
Stockley Park
Uxbridge
Middlesex
UB11 1TD
Tel: +44 (0) 20 7160 2500
Web: http://www.almirall.com/webcorp2/cda/index.jsp
Almirall is an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain. Almirall researches, developes, produces and markets proprietary R&D medicines and those under licence with the aim of improving people’s health and wellbeing.
The therapeutic areas on which Almirall focuses its research resources are related to the treatment of:
x Asthma,
x COPD (Chronic Obstructive Pulmonary Disease),
x Rheumatoid arthritis,
x Multiple sclerosis,
x Psoriasis,
x Dermatology
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
The signing of an agreement on the terms of a future trade relationship between Japan and the UK has been welcomed by the UK pharma industry, which counts Japan as…
US Merck (MSD globally) is following through on a 2017 commitment to invest in a new early research hub in central London, with plans to open the ‘London Discovery Research…
Jameel Zayed of Leyton, the UK’s leading innovation funding consultancy, highlights the British pharmaceutical industry’s rapid response to COVID-19 and the three ways in which the sector is driving national…
Below we highlight some recent developments in pharma and healthcare in the UK, including drug shortages in British intensive care units (ICUs), COVID-19 drug trials, biotech deals and market access…
The world’s two leading vaccine producers, GSK of the UK and France’s Sanofi, last week announced that they are working together to develop a vaccine for the novel coronavirus (COVID-19);…
With Brexit now confirmed, the UK government has been playing up the country’s scientific credentials. The aim is to cement the UK’s position as one of the world’s top life…
Friday January 31 2020 was officially dubbed “Brexit Day” as the UK finally left the EU, following British Prime Minister Boris Johnson’s sweeping election victory on a promise to “Get…
Although biotech financing in the UK took a hit last year in large part thanks to uncertainty around Brexit, 2019 was still the British industry’s third-best year on record. …
GW Pharmaceuticals reports that sales of its CBD drug Epidiolex more than doubled in the second quarter of 2019, demonstrating that cannabinoid-based medicines can be highly profitable and potentially blazing…
Formed in 2015, listed UK start-up Amryt targets rare diseases with high unmet medical need. With one commercial asset on the market, a strong pipeline of development assets and a…
Hopes have been raised of a cure for AIDS after a patient in London became free of the HIV virus following a bone marrow transplant. Although it is not…
Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis in the UK. True pioneers, they are…
See our Cookie Privacy Policy Here
